SCHEMBL1818765

SCHEMBL1818765

CCC(C)C(N)C(=O)NCCN1CCOCC1.O=S(=O)(O)OS(=O)(=O)O

nearest known ligand 0.82

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.50
▸ ALDH1A1 P00352 3/20 0.48
▸ TDP1 Q9NUW8 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.42
▸ TLR2 O60603 1/20 0.42
▸ MMP3 P08254 2/20 0.41
▸ MMP9 P14780 2/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ BCHE P06276 1/20 0.39
▸ ACHE P22303 1/20 0.39
▸ MMP1 P03956 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1815850 1.00 TSHR (0.50) TSHRALDH1A1TDP1NPSR1TLR2
Sulfuric Acid SCHEMBL29684494 0.93 TSHR (0.54) TSHRALDH1A1TDP1NPSR1TLR2
Sulfuric Acid SCHEMBL1815849 0.93 TSHR (0.54) TSHRALDH1A1TDP1NPSR1TLR2
SCHEMBL1818338 0.93 TSHR (0.54) TSHRALDH1A1TDP1NPSR1TLR2
Sulfuric Acid SCHEMBL19900361 0.93 TSHR (0.54) TSHRALDH1A1TDP1NPSR1TLR2
Sulfuric Acid SCHEMBL19837752 0.93 TSHR (0.54) TSHRALDH1A1TDP1NPSR1TLR2
Sulfuric Acid SCHEMBL1818768 0.93 TSHR (0.54) TSHRALDH1A1TDP1NPSR1TLR2
SCHEMBL1819631 0.93 TSHR (0.54) TSHRALDH1A1TDP1NPSR1TLR2
Sulfuric Acid SCHEMBL31198220 0.93 TSHR (0.54) TSHRALDH1A1TDP1NPSR1TLR2
SCHEMBL27893120 0.92 TSHR (0.53) TSHRALDH1A1TDP1NPSR1TLR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3470402-A1 CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS Pharmatrophix Inc. (US) 2019-04-17 — — EP claimed
US-9271986-B2 Crystalline forms of neurotrophin mimetic compounds and their salts PHARMATROPHIX, INC. (US) 2016-03-01 — — US claimed
US-20150259278-A1 CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS PHARMATROPHIX, INC. 2015-09-17 — — US claimed
EP-2900646-A1 CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS Pharmatrophix Inc. (US) 2015-08-05 — — EP claimed
US-20130005731-A1 CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS PHARMATROPHIX, INC. (US) 2013-01-03 — — US claimed
WO-2024192470-A1 METHOD OF TREATING GLIOBLASTOMA OR OTHER CANCERS EXPRESSING P75 NEUROTROPHIN RECEPTOR THE UNIVERSITY OF NEWCASTLE (AU) 2024-09-26 — — WO disclosed
EP-3470402-B1 CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS PHARMATROPHIX INC (US) 2021-01-06 — — EP disclosed
EP-3470402-A1 CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS Pharmatrophix Inc. (US) 2019-04-17 — — EP disclosed
EP-2498782-B1 CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS PHARMATROPHIX INC (US) 2019-01-09 — — EP disclosed
US-20180037559-A1 CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS PHARMATROPHIX, INC. 2018-02-08 — — US disclosed
US-9884833-B2 Crystalline forms of neurotrophin mimetic compounds and their salts PHARMATROPHIX, INC. (US) 2018-02-06 — — US disclosed
US-9884833-B2 Crystalline forms of neurotrophin mimetic compounds and their salts PHARMATROPHIX, INC. (US) 2018-02-06 — — US disclosed
US-20150259278-A1 CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS PHARMATROPHIX, INC. 2015-09-17 — — US disclosed
US-20150259278-A1 CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS PHARMATROPHIX, INC. 2015-09-17 — — US disclosed
EP-2900646-A1 CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS Pharmatrophix Inc. (US) 2015-08-05 — — EP disclosed
EP-2900646-A1 CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS Pharmatrophix Inc. (US) 2015-08-05 — — EP disclosed
WO-2014052659-A1 CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS PHARMATROPHIX, INC. (US) 2014-04-03 — — WO disclosed
US-20130005731-A1 CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS PHARMATROPHIX, INC. (US) 2013-01-03 — — US disclosed
EP-2498782-A1 CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS Pharmatrophix Inc. (US) 2012-09-19 — — EP disclosed
WO-2011060262-A1 CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS PHARMATROPHIX, INC. (US) 2011-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259278-A1 CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS BDNF, NTRK2, NGF TSHR 1550/4885ALDH1A1 3092/4885TDP1 2315/4885
US-20180037559-A1 CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS BDNF, NGF, NTRK2 TSHR 885/4885ALDH1A1 4396/4885TDP1 1256/4885
US-20130005731-A1 CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS BDNF, NGF, NTRK2 TSHR 885/4885ALDH1A1 4396/4885TDP1 1256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback